Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Immunotherapy + Hormone Therapy for Prostate Cancer
Recruiting1 awardPhase < 1
New York, New York
This trial is testing if adding a new drug (BMS-986218) to a hormone therapy (degarelix) before surgery can better prevent prostate cancer from returning. It targets men with high-risk localized prostate cancer. The new drug helps the immune system fight cancer, while the hormone therapy lowers testosterone to slow cancer growth. Degarelix is used to treat prostate cancer by rapidly lowering testosterone levels.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service